Revisión sistemática
No clasificado
Sin referencias
Resumen estructurado de revisiones sistemáticas
No clasificado
Resumen estructurado de revisiones sistemáticas
No clasificado
Estudio primario
No clasificado
Este artículo está incluido en 39 Revisiones sistemáticas Revisiones sistemáticas (39 referencias)
<b>
Estudio primario
No clasificado
Este artículo está incluido en 30 Revisiones sistemáticas Revisiones sistemáticas (30 referencias)
<b>
Revisión sistemática
No clasificado
Sin referencias
Studies of ipilimumab have shown improved overall survival in patients with metastatic cutaneous melanoma. As a result, use of ipilimumab in patients with Stage IV melanoma is rapidly increasing. Patients with Stage IV melanoma often require urgent operations for complications from metastases, but little is known about the safety of surgical intervention for patients receiving ipilimumab. We performed a systematic review of the literature using PubMed. Our search terms were melanoma and ipilimumab. We excluded foreign language articles, review articles, and those not addressing cutaneous melanoma. We identified 194 publications matching the search criteria. Only six of those met the inclusion criteria. In these six publications, seven patients who had undergone surgical intervention during treatment with ipilimumab were described. There were no documented surgical complications. We reviewed our institutional experience and identified an additional three patients. No postoperative complications could be attributed directly to ipilimumab. There are limited data on the safety of surgical intervention during treatment with ipilimumab. Preliminary reports suggest there is no reason to withhold or delay surgery for patients receiving ipilimumab therapy.
Estudio primario
No clasificado
Este artículo no está incluido en ninguna revisión sistemática
Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.
Resumen estructurado de revisiones sistemáticas
No clasificado
Resumen estructurado de revisiones sistemáticas
No clasificado
Estudio primario
No clasificado
Este artículo está incluido en 27 Revisiones sistemáticas Revisiones sistemáticas (27 referencias)
<b>